Advances in research on the mechanism of propranolol in the treatment of infantile hemangiomas

doi:10.19438/j.cjoms.2020.02.019

Abstract

CLC Number:

R739.8

SONG Hui-xin, LIN Chun-nan, WANG Tian-you, FU Zhao-chen. Advances in research on the mechanism of propranolol in the treatment of infantile hemangiomas[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(2): 182-185.

References

[1] Phung TL, Hochman M.Pathogenesis of infantile hemangioma[J]. Facial Plast Surg, 2012, 28(6): 554-562.
[2] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al.Propranolol for severe hemangiomas of infancy[J].N Engl J Med, 2008, 358(24): 2649-2651.
[3] Storch CH, Hoeger PH.Propranolol for infantile hemangiomas:insights into the molecular mechanisms of action[J]. Br J Dermatol, 2010, 163(20): 269-274.
[4] Cavalli R, Buffon RB, de Souza M, et al. Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?[J]. Dermatology, 2012, 224(2): 106-109.
[5] Lee D, Boscolo E, Durham JT, et al.Propranolol targets the contractility of infantile haemangioma-derived pericytes[J]. Br J Dermatol, 2014, 171(5): 1129-1137.
[6] Pan WK, Li P, Guo ZT, et al.Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway[J]. Pediatr Blood Cancer, 2015, 62(8): 1414-1420.
[7] D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation[J].J Cell Biochem, 1997, 67(3): 353-366.
[8] Storch CH, Hoeger PH.Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action[J]. Br J Dermatol, 2010, 163(2): 269-274.
[9] Ozeki M, Nozawa A, Hori T, et al.Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor[J]. Pediatr Int, 2016, 58(11): 1130-1135.
[10] 赵忠芳, 吕仁荣, 霍然, 等. 普萘洛尔治疗增生期血管瘤患儿血清中血管内皮生长因子及基质金属蛋白酶9的变化[J]. 中华整形外科杂志, 2011, 27(5): 359-361.
[11] 高健, 徐潇. 普萘洛尔对婴幼儿血管瘤患者尿液中基质金属蛋白酶(MMPs)表达水平的影响[J]. 中国美容整形外科杂志, 2017, 28(5): 299-301.
[12] Bokoch MP, Zou Y, Rasmussen SG, et al.Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor[J]. Nature, 2010, 463(7277): 108-112.
[13] de Jong S, Itinteang T, Withers AH, et al. Does hypoxia play a role in infantile hemangioma?[J]. Arch Dermatol Res, 2016,308(4): 219-227.
[14] 杨艳萍, 张国珍, 张云艳. DLL4蛋白在恶性肿瘤中的研究进展[J]. 现代肿瘤医学, 2016, 24(22): 3687-3690.
[15] Sun B, Dong C, Lei H, et a1. Propranolol inhibits proliferation and invasion of hemangioma-derived endothelialcells by suppressing the DLL4/Notch1/Akt pathway[J]. Chem Biol Interact, 2018, 18(24): 28-33.
[16] Li S, Xu G, Gao F, et al.Expression and association of VEGF-Notch pathways in infantile hemangiomas[J]. Exp Ther Med, 2017, 14(4): 3737-3743.
[17] Li D, Li P, Guo Z, et al.Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway[J]. Int J Mol Med, 2017, 39(3): 757-763.
[18] 凌彬, 陈曼丽, 刘洁, 等. 普萘洛尔治疗增殖期血管瘤患者血管内皮生长因子A及表皮生长因子样结构域7 的表达分析[J]. 华西口腔医学杂志, 2014, 32(5): 441-445.
[19] 周昱川. 色素上皮衍生因子在普萘洛尔治疗婴幼儿血管瘤中的作用机制[D]. 乌鲁木齐:新疆医科大学, 2017.
[20] Itinteang T, Marsh R, Davis PF, et al.Angiotensin Ⅱ causes cellular proliferation in infantile haemangioma via angiotensin Ⅱ receptor 2 activation[J]. J Clini Pathol, 2015, 68(5): 346-350.
[21] 范桂权. CD39在普萘洛尔治疗血管瘤裸鼠模型中的作用机制探讨[D]. 泸州:泸州医学院, 2013.
[22] 何辉霞. 普萘洛尔诱导血管内皮细胞凋亡对P38MAPK信号通路影响的体外实验研究[D]. 泸州:泸州医学院, 2014.
[23] Tu JB, Ma RZ, Dong Q, et al.Induction of apoptosis in infantile hemangioma endothelial cells by propranolol[J]. Exp Ther Med, 2013, 6(2): 574-578.
[24] Wong A, Hardy KL, Kitajewski AM, et al.Propranolol accelerates adipogenesis in hemangioma stemcells and causes apoptosis of hemangioma endothelial cells[J]. Plast Reconstr Surg, 2012, 130(5): 1012-1021.
[25] England RW, Hardy KL, Kitajewski AM, et al.Propranolol promotes accelerated and dysregulated adipogenesis in hemangioma Stemclls[J]. Ann Plast Surg, 2014, 73(1): 119-124.
[26] Yao TH, Pataer P, Regmi KP, et al.Propranolol induces hemangioma endothelial cell apoptosis via a p53-BAX mediated pathway[J]. Mol Med Rep, 2018, 18(1): 684-694.
[27] Ma XR, Zhao TH, Ouyang TX, et al.Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells[J]. Int J Clin Exp Pathol, 2014, 7(7): 3809-3817.